

August 10, 2021

To,

Department of Corporate Service BSE Limited.

Registered Office: Floor 25, P. J. Towers,

Dalal Street, Fort, Mumbai 400001. MAHARASHTRA.

T: 2272 1233 / 1234 | F: 2272 3121 / 3719 | www.bseindia.com

Subject

: Approval of Standalone Un-Audited Financial Results for the

quarter ended June 30, 2021.

Reference : Centenial Surgical Suture Ltd. | Scrip Code: 531380

Sir,

In pursuance of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit following documents:

- 1). Standalone Un-Audited Financial Results for the quarter ended June 30, 2021.
- 2). Limited Review Report for the quarter ended June 30, 2021.

You are requested to kindly take the same on your record.

मुखाड

For CENTENIAL SURGICAL SUTURE LTD.

Wijay MAJREKAR
Managing Director & Chief Executive Officer
DIN: 00804808

Encl: as mentioned above.

Registered Office
F-29, MIDC, Murbad, Thane 421401.
MAHARASHTRA.
C912524222905 Fax 912524222905

Manufacturing Facility
B-17 / F-29 / F-22 MIDC, Murbad,
Thane 421401. MAHARASHTRA.
\$\(\) 2524223200 Fax 912524 222872

Sales Office - Mumbai

1st Floor, Palai Complex CH5 Ltd.,
Bhandarkar Road, Matunga (East),

Mumbai 400019. MAHARASHTRA.

912224102876 Fax 912224161261

Sales Office - Bengaluru
No.12742. Udhani Lavout

No.12/42, Udhani Layout, Off. Cambridge Road, Halasur, Bengaluru 560008. KARNATAKA. C 9180 25577791 Fax 9180 25577792

Sales Office - Kolkata
Flat No. N-1, Ground Floor, 385,
Purbachal, Kalitala Road, P.S. Kasba,
Kolkata 700078. WEST BENGAL.
91 3324844875 Fax 91 3324844875

Statement of Standalone Un-Audited Financial Results for the Quarter ended June 30, 2021

(Rs. In Lakhs, unless otherwise stated)

C- 11	Particulars	Quarter ended			Year ended	
Sr. No.		30/06/2021	31/03/2021 (Audited)	30/06/2020 (Unaudited)	31/03/2021 (Audited)	
		(Unaudited)				
-	Revenue from Operations	837.28	1283.98	602.39	3693.30	
- 11	Other Income	0.02	8.68	0.47	9.26	
111	Total Revenue (I + II)	837.29	1292.66	602.85	3702.56	
IV	Expenses :					
	(a) Cost of Materials Consumed	267.83	502.92	327.57	1581.21	
	(b) Purchases of Stock-in-Trade			-		
	(c) Changes in Inventories of Finished Goods, Work-in-Progress & Stock-in-Trade	45.73	237.42	(273.21)	(544.79	
	(d) Employee Benefits Expense	245.23	252.97	224.07	997.98	
	(e) Finance Costs	45.41	65.75	25.13	201.68	
	(f) Depreciation and Amortisation Expense	36.54	36.96	38.36	155.08	
	(g) Other Expenses	186.09	180.76	239.59	1158.41	
	Total expenses (IV)	826.83	1276.77	581.51	3549.57	
٧	Profit / (Loss) before Exceptional items and Tax (III - IV)	10.46	15.88	21.34	152.99	
VI	Exceptional Items					
VII	Profit / (Loss) before Tax (V-VI)	10.46	15.88	21.34	152.99	
VIII	Tax Expense :	10.10	13.00	21.54	132,33	
	(1) Current Tax	2.91	19.49	5.55	54.00	
	(2) Deferred tax		13.13	3.33	2.81	
	Total Tax Expenses	2.91	19.49	5.55	56.81	
IX	Profit / (Loss) for the period form Continuing Operations (VII -VIII)	7.55	(3.61)	15.79	96.18	
X	Profit / (Loss) from Discontinued Operations	7.55	(3.01)	13.73	36.16	
XI	Tax expenses of Discontinued Operations					
XII	Profit / (Loss) From Discontinuing Operations (after tax) (X-XI)					
XIII	Profit / (Loss) for the period (IX+XII)	7.55	(2.51)	45.70	-	
XIV	Other Comprehensive Income	7.55	(3.61)	15.79	96.18	
	A. (1) Items that will not be reclassified to profit or loss		-	-	-	
	(ii) Income tax relating to items that will not be reclassified to profit or loss	•	•	•	•	
	B. (I) Items that will be reclassified to profit or loss	•	•			
	(ii) Income tax relating to items that will be reclassified to profit or loss	•	•	•	•	
XV	Total Comprehensive Income for the period (XIII + XIV) (comprising Profit / (Loss)	7.55	(3.61)	15.79	96.18	
	for the period after tax and Other Comprehensive Income after tax)					
XVI	Details of Equity share capital					
	Paid up Equity capital (Face Value of Rs.10/- each)	364.83	364.83	364.83	364.83	
	Face value of Equity Share Capital	10.00	10.00	10.00	10.00	
XVII	Earnings Per Equity Share (for Continuing operation):					
	(a) Basic	0.21	(0.10)	0.43	2.64	
	(b) Diluted	0.21	(0.10)	0.43	2.64	
XVIII	Earnings Per equity share (for Discontinued operation) :					
	(a) Basic	-	-			
	(b) Diluted	2				
XIX	Earnings Per Equity Share (for Discontinued & Continuing operation):					
	(a) Basic	0.21	(0.10)	0.43	2,64	
	(b) Diluted	0.21	(0.10)	0.43	2.64	

- The Company has one reportable business segment "Medical Devices". 1).
- 2). The above Statement of Standalone Unaudited Financial Results for the quarter ended June 30, 2021 ("Statement") is prepared in accordance with Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The Statement is, as reviewed by the Audit Committee, considered and approved by the Board of Directors at its meeting held on 10th August, 2021. The Statement is subjected to 'limited review' by the Auditors of the Company and their report contains no qualification.
- 3). In accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, the Statutory Auditors have carried out a Limited Review of the Standalone Un-Audited Financial Results for the quarter ended June 30, 2021.



4). Impact of COVID-19 Pandemic

The COVID-19 outbreak has spread rapidly during the last financial year. Governments across the globe, including in India, have undertaken various measures to contain the spread of this virus including restrictions on travel, social distancing, and other emergency measures. These measures have had a direct impact on our business and have affected the supply chains and production of our medical devices. Lower economic activity has also resulted in the supressed demand for our medical devices. Our Company experienced delays in delivery of supplies to hospitals and nursing homes due to restrictions on courier services. In view of the lockdown and curfew announced across many states in India, the Company has undertaken and strengthened various measures to ensure the safety and well-being of its employees and has focused on continued delivery of medical devices across the country, by ensuring that its key functions i.e. procurement, manufacturing, supply chain, marketing, sales and support functions continue to operate smoothly. Management has considered its liquidity position as at June 30, 2021 and over the next nine months from the date of approval of these financial statements, and has concluded that the Company may face liquidity in the course of business.

5). The unaudited results for the Quarter ended June 30, 2021 are available on the website of BSE Limited at www.bseindia.com and on Company's website at www.centenialindia.com.

A Para

Vijay MAJREKAR

L SURGICAL SUTURE LTD.

for and on behalf of the Board of Directors of

Managing Director & Chief Executive Officer DIN: 00804808

Place : Mumbai, Maharashtra Date : August 10, 2021

Mahesh Chandra & Associates

Chartered Accountants

Independent Auditor's Review Report on the Quarter ended June 30, 2021 Standalone Un-Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

Review Report to
The Board of Directors of
CENTENIAL SURGICAL SUTURE LTD.

Registered Office: F-29, M.I.D.C., Murbad, Thane 421401. MAHARASHTRA.

- a. We have reviewed the accompanying Statement of Standalone Un-Audited Financial Results of Centenial Surgical Suture Limited ("the Company") for the quarter ended June 30, 2021 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended ('the Regulation') read with SEBI Circular No: CIR/CFD/CMD1/44/2019 dated March 29, 2019 ('the Circular').
- b. This "statement" which is the responsibility of the Company's Management and approved by the Board of Directors at their meeting held on August 10, 2021 has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.
- c. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- d. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For M/s Mahesh Chandra & Associates

Chartered Accountants, Firm Registration No.: 112334W



RAJESH BOHRA

Partner ~ Membership No.102587 UDIN: 21102587AAAAKT1671

Place: Mumbai, MAHARASHTRA

Date: August 10, 2021